Location:HOME >> Famous Scholars
Directory By Name
                                             
Name: Li lanjuan
Post Professor
Position: Director of the State Key Laboratory for Infectious Diseases Diagnosis and Treatment
Education M.D.
Professional Infectious Diseases
Departments The First Affiliated Hospital
Research liver failer and artificial liver supporting system,microecology
TEL: 0571-87236458
E-mail: ljli@zju.edu.cn
Personal Home Page: http://mypage.zju.edu.cn/0007106  

Profile
CURRICULUM VITAE
Dr. Lanjuan Li
Professor of Infectious Diseases
Director, State Key Laboratory for Infectious Diseases

PERSONAL INFORMATION:
Professor Lanjuan Li, born on September, 1947, is a member of CAE (Chinese Academy of Engineering) and Professor/Chief Physician of Infectious Diseases, The First Affiliated Hospital of Zhejiang University School of Medicine. She also serves as the Director of the State Key Laboratory for Infectious Diseases Diagnosis and Treatment, academic leader of both national key discipline of infectious diseases and national 211 construction discipline. She has been engaged in clinical, teaching and research work of infectious diseases for over 30 years, published more than 300 articles. Professor Li is of great attainments in the country both in treating viral hepatitis, particularly in treating severe hepatitis with artificial liver supporting system, and in microecology. She is a pioneer in the study of artificial liver in the country.

ADDRESS /CONTACT INFORMATION:
State Key Laboratory for Infectious Diseases Diagnosis and Treatment
First Affiliated Hospital,
Zhejiang University School of Medicine
79, Qingchun Road, Hangzhou City (310003)
Zhejiang Province, P.R of China

TEL: 0086-571-87236458
FAX: 0086-571-87236459
E-mail:ljli@zju.edu.cn

PROFESSIONAL ACTIVITIES
Member of CAE (Chinese Academy of Engineering)
Professor and Chief Physician, Department of Infectious Diseases, The First Affiliate Hospital, Zhejiang University School of Medicine
Director of State key laboratory for Infectious Diseases diagnosis and treatment
Academy leader of Internal Medicine (Infectious Diseases) State Key Discipline
Chair of Science and Technology Association, Zhejiang Province
Vice president of Chinese Medical Association
Vice president of Chinese Health Information Society
Associate Board Chairperson of Chinese Society of Biomedical Engineering
Chief, Infectious Diseases Division, China Medical Association
Group Leader, Liver Failure and Artificial Liver Group, Infectious Diseases Division, China Medical Association
Associate Division Chief, Microecology Branch, China Preventive Medicine Association
President, Infectious Diseases Doctor Branch, Chinese Medical Doctor Association
Director, National Artificial Liver Training Center
Academic Member, International Hepatic Diseases Research and Cooperation Exchange Centre
Chief Editor of “Chinese journal of Clinical Infectious Diseases”, “Chinese Journal of Microecology” and “Zhejiang Medical Journal”; Vice Chief Editor of “Chinese Journal of Infectious Diseases” and “International Journal of Epidemiology and Infectious Disease”

MAJOR ACCOMPLISHMENTS IN CLINICAL AND RESEARCH
Dr. Lanjuan Li has more than 30 years of experience of clinic, research and teaching in the field of infectious diseases. She has achieved initiative success in the diagnosis and treatment of infectious diseases and made important contributions to the diagnosis and treatment of infectious diseases in China. The main research interests of Dr. Li are focused on: infectious diseases diagnosis and treatment, liver failure and artificial liver and infectious microecology. She established an special and effective artificial liver support system(ALSS), which acquired momentous breakthrough in the treatment of severe hepatitis, greatly improved the its cure rate and pioneered an new avenue in the treatment of severe hepatitis. She also established the first immortalized hepatocyte cell line—HepLL in China, a new method in isolating hepatocytes and new type bioartificial liver and mixed artificial liver. She actively generalized the ALSS technology to more than 300 hospitals in 30 provinces and cities around the country. She organized and constituted the liver failure and artificial liver group, infectious diseases branch, Chinese Medical Association. She emceed and set down “Guide of Artificial liver treatment” and “Guide of Liver Function Failure Diagnosis and Treatment”, compiled “Artificial Liver” -- the first monograph in this field in China, all of which improved the standardization of artificial liver clinical application in China and lead the Chinese artificial liver research development direction. These attributions won the first prize of science and technology advancement, Zhejiang Province in 1997 and 2007, and the second prize of State Science and Technology in 1998.

Dr. Li generated the new theory on infectious microecology, established a infectious microecology research platform, conducted serial research on liver diseases microecology and bacterial resistance, for the first time uncovered the mechanism of microecology imbalance in the occurrence and development of liver failure, bring out the new strategy of infectious microecology prevention and treatment, edited the first monograph “ Infectious Microecology” in China, settled the foundation of infectious microecology. Her production won the first prize of Science and Technology Advancement, Zhejiang Province in 2001 and 2003 and the second prize of State Science and Technology in 2007. In the battle against SARS, she brought forward and practiced a serial of measures which exerted key function in assuring no second generation patient, no medical personnel infection and effective cure of severe patients, and she also led her group to carry out in-depth research about SARS virus. In 2003, she timely edited and published a monograph “Infectious Atypical Pneumonia” which generated active effect in guiding the prevention and treatment of “SARS”. The research production won the second prize of Science and Technology Advancement, Zhejiang Province in 2004. 2008.6, she edited and published a monograph “Hand Foot and Mouth Diseases”, the book and its electronic edition were donated to the ministry of health and they served as a relatively complete and useful reference book to the large health worker. Recently, she proposes to carry out a “heath face to face” action plan, and as a chief principal she is also in charge with the state science and technology support plan subjects “State digital health key technology and area demonstration application research” project, the goal of which is to implement digital health and endeavor for health China.
For the recent years, over 300 papers are published on the journals home and abroad such as Journal of Hepatology, Journal of Clinical Virology. She is charged with over 10 projects: state 863, 973, tenth five-year plan tackling key problems, state nature science foundation key project. As the first prizewinner, she won 2 second prizes for state science and technology advancement, 4 first prizes for science and technology advancement, Zhejiang Province, 1 second prize for state educational ministry university generalization and application; she was authorized 7 patents, published 15 monographs among of which the “Epidemiology” is the education ministry national wide university medical programming textbook and is appraised as national excellent course.

Major Publications:
Editor-in-chief for 15 books and joint-editors for 9 books
Doctor Choosing Guide in Zhejiang, author, 1999, China Environmental Science Press
Bacteria Toxin and Clinical Treatment, author, 1999,People’s Health Press
Artificial Liver, author, 2001, Zhejiang University Press
Infectious Microecology, author, 2001, People’s Health Press
Teaching Materials for General Practitioners, Member of Editing Committee, 2001, Sichuan Science & Technology Press
Prevention and Care for Chronic Diseases, author, 2001, Sichuan Science & Technology Press
Zhejiang Provincial Hospital Management and Technical Regulation Series, author, 2003, Zhejiang University Press
Infectious Diseases, author, 2003, Higher Education Press
Infectious Severe Acute Respiratory Syndrome, author, 2003, Zhejiang Provincial Science & Technology Press
prevention and cure of infection diseases,author, 2006,era economy Press

Medicine-Prevention Conformity—Medical institution Public Health working Theory and Practice, author, 2007, Zhejiang Science and Technology Press
Medical Affairs management practical handbook, author, 2008, Zhejiang University Press
Drug use of common diseases in Infectious department, author, 2008, People’s Health Press
Hand, Foot and Mouth Disease, author, 2008, Zhejiang Technology and Science Press
Epidemiology retrospection actuality and prospect, author, 2008, People’s Health Press

Major Research Funding:
1. Project Principal: Mixed Artificial liver support system construction and application research, tenth five-year plan tackling key problem subject (2004BA706B02-01),2004.7-2005.12,¥1,200,000
2. Project Principal: Relationship and interruption research between microecology imbalance and CGD after organ transplantation, national 973 tackling key problem project (2003CB515506),2003.12-2008. ¥112,000,000
3. Project Principal: High efficacy mixed artificial liver system construction and function evaluation, national nature science foundation (30270369),2003.1-2003.12,¥70,000
4. Project Principal: Mixed artificial liver construction and clinical application, Zhejiang Province Bureau of Science and Technology key project (021107689),2003.1~2005.12,¥500,000
5. Project Principal: Etiology and prevention strategy research of SARS in Zhejiang Province (G20030548),2003.4~2004.12,¥500,000
6. Project Principal: Construction of human hepatocyte cell line and its application in artificial liver, national nature science foundation (30170255)
7. Project Principal: Mixed artificial liver application research, National 863 Major special subjects (2003AA205150),2003.1-2005.12,¥1,500,000
8. Project Principal: Differentiation of embryo stem cell to hepatocyte and its application research in severe hepatitis treatment, Zhejiang Province Bureau of Science of Technology key project (021103126),2002.1-2004.12,¥300,000
9. Project Principal: Functional research of HBV Pre-S2 gene variation in severe hepatitis pathogenesis, Zhejiang Province Medicine health key Science and Technology project (G20020302),2002. 7 -2004. 12
10. Project Principal: Reversible human immortalized hepatocyte cell line construction and its use in bioartificial liver, National nature science foundation key project (30630023),2007.1-2010.12,¥1,100,000
11. Second Principal: New type bioartificial liver development and application, National high technology research and development plan (863计划, 2006AA02A140)), 2006.12-2010.12 ,¥5,680,000
12. Project Principal: Human avian flu block technique investigation, National Science and Technology supporting plan, (2006BAD06A15)2006.1-2010.12,¥750,000
13. Project Principal: Relationship between gut microecology imbalance and liver diseases and its interruption research, National 973 project, 2007.8-2011.12,¥4,738,400

Selected Publications (from total over 200)
1、 Pi B, Yu M, Chen Y, Yu Y, Li L.Distribution of the ACME-arcA gene among meticillin-resistant Staphylococcus haemolyticus and identification of a novel ccr allotype in ACME-arcA-positive isolates.J Med Microbiol. 2009 Jun;58(Pt 6):731-6
2、 Jiang Y, Zhou Z, Qian Y, Wei Z, Yu Y, Hu S, Li L .Plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China. J Antimicrob Chemother. 2008 May;61(5):1003-6
3、 Shen P, Jiang Y, Zhou Z, Zhang J, Yu Y, Li L.J. Complete nucleotide sequence of pKP96, a 67 850 bp multiresistance plasmid encoding qnrA1, aac(6')-Ib-cr and blaCTX-M-24 from Klebsiella pneumoniae. Antimicrob Chemother. 2008 Dec;62(6):1252-6
4、 Diao H, Iwabuchi K, Li L, Onoe K, Van Kaer L, Kon S, Saito Y, Morimoto J, Denhardt DT, Rittling S, Uede T.Osteopontin regulates development and function of invariant natural killer T cells. Proc Natl Acad Sci U S A. 2008 Oct 14;105(41): 15884-9
5、 Li M, Wang B, Zhang M, Rantalainen M, Wang S, Zhou H, Zhang Y, Shen J, Pang X, Zhang M, Wei H, Chen Y, Lu H, Zuo J, Su M, Qiu Y, Jia W, Xiao C, Smith LM, Yang S, Holmes E, Tang H, Zhao G, Nicholson JK, Li L, Zhao L. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2117-22
6、 Shiping Ding, Lanjuan Li(Corresponding author), Xiufang Zhu. Polymorphism of the interferon-gene and risk of tuberculosis in a southeastern Chinese population. Human Immunology,2008 Feb;69(2):129-33
7、 Xiaoli Liu, Lanjuan Li(Correspondence), Guoyi Zhang, Guoping Sheng a, Wei Xu. An approach to the characterization of serum low-molecular weight proteins/peptides in liver injury using SELDI–TOF MS and factor analysis. Clinical Biochemistry,2007, 40:1266–1271
8、 Y.-S. CHEN, Z.-W. WU, J.-Q. HE, G.-P. SHENG, Y.-M. ZHANG, J. YU, H.-C. CAO, W.-B. DU, L.-J. LI. The curative effect of ALSS on 1-month mortality in AoCLF patients after 72 to 120 hours. The International Journal of Artificial Organs , 2007 Oct;30(10):906-14
9、 X. P. Pan, L. J. Li(Correspondence), W. B. Du, M. W. Li, H. C. Cao and J. F. Sheng. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudineresistant hepatitis B genotypes B and C. Journal of Viral Hepatitis, 2007, 14, 767–774
10、 Shi-Gui Yang, Hong-Jun Dong , Fu-Rong Li , Shu-Yun Xie ,Hong-Cui Cao , Shi-Chang Xia , Zhao Yu , Lan-Juan Li(Correspondence).Report and analysis of a scarlet fever outbreak among adults through food-borne transmission in China. Journal of Infection,2007,55, 419-424
11、 Ke Yu, Guoping Sheng, Jifang Sheng,Yuemei Chen,Wei Xu,Xiaoli Liu, Hongcui Cao,Haibin Qu, Yiyu Cheng,and Lanjuan Li. A Metabonomic Investigation on the Biochemical Perturbation in Liver Failure Patients Caused by Hepatitis B Virus. Journal of Proteome Research, 2007, 6, 2413-2419
12、 Chen C, Li L, Wu Z, Chen H, Fu S. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis. J Infect. 2007 Jan;54(1):98-102
13、 ZHANG ChunChao,ZHU Feng,WEI JianFeng,ZHENG ShuSen & LI LanJuan.A proteomic analysis of allograft rejection in rats after liver transplantation,Science in China Series C:Life Sciences,2007,50(3):312-319
14、 T. Xing, L. Li, H. Cao and J. Huang. Altered immune function of monocytes in different stages of patients with acute or chronic liver failure. Clinical and Experimental Immunology, 2006, 147: 184–188
15、 Yu Chen, Wei Wu, Lan-juan Li*,et al. Comparison of the results for three automated immunoassay systems in determining serum HBV markers. Clinica Chimica Acta, Clin Chim Acta. 2006 ,Oct;372(1-2):129-33
16、 Lan Juan Li*, Yi Min Zhang, Xiao Li Liu, Wei Bo Du, Jian Rong Huang, Qian Yang, Xiao Wei Xu, Yue Mei Chen. Artificial Liver Support System in China: A Review Over the Last 30 Years. Therapeutic Apheresis and Dialysis , 2006, 10(2):160–167
17、 Li J, Li L*, Yu H, Cao H, Gao C, Gong Y. Growth and Metabolism of Human Hepatocytes on Biomodified Collagen Poly(lactic-co-glycolic acid) Three-Dimensional Scaffold. ASAIO J. 2006 May/June;52(3):321-327
18、 FAN Jun,MA Wei-hang,YANG Mei-fang,XUE Han,GAO Hai-nv,LI Lan-juan*.Real-time fluorescent quantitative PCR assay for measuring cytomegalovirus DNA load in patients after haematopoietic stem cell transplantation,Chinese Medical Journal,2006,119(10):871-874
19、 XING Hui-chun, LI Lan-juan*, XU Kai-jin, SHEN Tian,CHEN Yun-bo, SHENG Ji-fang, YU Yun-song, CHEN Ya-gang. The protective role of supplement with foreign Bifidobacterium and Lactobacillus in experimental hepatic ischemia-reperfusion injury. Journal of Gastroenterology and Hepatology, 2006 Apr;21(4):647-56
20、 Lan Juan Li*, Wei Bo Du, Yi Min Zhang, Jun Li, Xiao Ping Pan,Jia Jia Chen, Hong Cui Cao, Yu Chen, Yue Mei Chen.Evaluation of a Bioartificial Liver Based on a Nonwoven Fabric Bioreactor with Porcine Hepatocytes in Pigs. J Hepatol, 2006, 44(2):317-324
21、 Chen, Y; Li, L*; Wu, W; Lou, B; Zhang, J; Fan, J.Comparison of the agreement of three automatic immunoassay systems for determining serum HBV markers. CLINICAL CHEMISTRY 2005,51 Suppl. 6: A178-A179
22、 L.Li*,W.Du,Y.Zhang,J.Li,X.Pan,J.Chen,H.Cao,Y.Chen,Y.Chen.Evaluation of a bioartificial liver based on nonwoven fabbic bioreactor with porcine hepatocytes in fulminant hepatic failure pigs . Int J Artif Organs 2005, 2005, 29(9):769
23、 L.J.Li*,Y.M.Zhang,J.Li,G.P.Sheng,H.Y.Yu. Biological characteristics of immortalized human hepatocyte (HepLL) after transplantation in spleen of BALB/c naked mice. Int J Artif Organs 2005, 28(9):927
24、 Li LJ*, Liu XL, Xu XW, Sheng GP, Chen Y, Chen YM, Huang JR, Yang Q. Comparison of plasma exchange with different membrane pore sizes in the treatment of severe viral hepatitis,Ther Apher Dial. 2005 ,9(5):396-401
25、 JUN LI, LAN-JUAN LI*, HONG-CUI CAO,et al. Establishment of Highly Differentiated Immortalized Human Hepatocyte Line With Simian Virus 40 Large Tumor Antigen for Liver Based Cell Therapy. ASAIO Journa. 2005; 51:262–268
26、 Wei Bo Du; Lanjuan Li*; Jian Rong Huang; Qian Yang; Xiao Li Liu; Jun Li; Yue Mei Chen; Hong Cui Cao; Wei Xu; Su Zhen Fu; Ya Gang Chen. Effects of Artificial Liver Support System on Patients with Acute on Chronic Liver Failure. Transplantation Proceedings,2005 Dec;37(10):4359-64
27、 Wan Zhigang,Li Lanjuan,Luo Yun,et al.Molecular biological analysis of genotyping and phylogeny of severe acute respiratory syndrome associated coronavirus. Chin Med J (Engl). 2004;117(1):42 48
28、 Li L*, Wo J, Shao J, Zhu H, Wu N, Li M, Yao H, Hu M, Dennin RH. SARS-coronavirus replicates in mononuclear cells of peripheral blood(PBMCs) from SARS patients. Journal of Clinical Virology,2003,28(3):239-244
29、 Li L, Wang Z, Lu Y,et al. Li L, Wang Z, Lu Y, Bao Q, Chen S, Wu N, Cheng S, Weng J, Zhang Y, Yan J, Mei L, Wang X, Zhu H, Yu Y, Zhang M, Li M, Yao J, Lu Q, Yao P, Bo X, Wo J, Wang S, Hu S. Severe acute respiratory syndrome-associated coronavirus genotype and its characterization. Chin Med J (Engl). 2003 Sep;116(9):1288-92
30、 ZHOU Zhihui, LI Lanjuan*, YU Yunsong, et al.The status of drug resistance and ampC gene express in Enterobacter cloacae. Chinese Medical Journal,2003,116(8):1244-1247
31、 Y. QIAN, L.LANJUAN, H.JIANRONG, et al.Study of severe hepatitis treated with a hybrid artificial liver support system. The International Journal of Artificial Organs, 2003,26(6):507-513
32、 Li L, Xu X, Lu F, Zhao N. Experimental study of ursodeoxycholic acid therapy in rats with intrahepatic cholestasis. Chinese Medical Journal, 2003,116(7):1099-1103
33、 Li LJ, Shen ZJ, Lu YL, et al.The Value of endotoxin concentrations in expressed prostatic secretions for the diagnosis and classification of chronic prostatitis. BJU International,2001,88:536-539
34、 Lanjuan L, Qian Y, Jianrong H, et al.Severe hepatitis treated with artificial liver support system. The International Journal of Artificial Organs,2001,24(5):297-303
35、 Lanjuan Li,Qian Yang,Jiangrong Huang,et al. Treatment of hepatic failure with artificial liver support system.Chinese Medical Journal,2001,114(9):941-945
36、 Li LJ, Wu ZW, Ma WH,et al.Changes of Intestinal Microflors and Their Roles in the Patients with Chronic Severe Hepatits. Chinese Medical Journal, 2001,114(8):869-872
37、 Li L, Shen Z,Wang H,Fu S,Cheng G.Investigation of infectious risk and the value of urine endotoxin during ESWL. Chinese Medical Journal, 2001,114(5):510-513